BSF Enterprise discusses the recent bleeding edge developments across its bio-engineering portfolio

Marcelo Bravo, Chief Business Officer at BSF Enterprise PLC (LSE: BSFA), (OTCQB: BSFAF), the UK listed tissue-engineering biotech company, sits down with focus IR to talk through their latest achievements across the portfolio and recent developments for lab grown leather and corneal replacement. In this interview, investors will also learn: - Why the Company’s Lab Grown Leather is ‘real leather’ as opposed to bio-alternatives - How the Company replicated the smell, strength and flexibility of real leather - What stage discussions with several luxury goods houses are at - Why the Company established a wholly owned subsidiary, Ketato Ltd, to develop novel solutions for the treatment of corneal tissue damage - What additional ‘media’ alternatives are ready for commercialisation Reasons to add Bio-Sustainable Future Enterprise PLC (BSFA) to your watchlist: - BSFA is developing cutting edge tissue-engineering IP - BSFA is currently industrialising lab production protocols and commercialising its IP across several applications with large addressable end markets including: -- Luxury Leather Goods – Wholly owned subsidiary, Lab Grown Leather Ltd, is producing and ready to commercialise lab-grown leather for the ethical luxury goods market -- Corneal Tissue Replacements - Wholly owned subsidiary, Kerato Ltd, is commencing in pet trials for the companion animal market with human medical trials expected to follow in due course For further information, visit www.bsfenterprise.com and keep up to date with developments by adding BSFA to your watchlist.